<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37214">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622074</url>
  </required_header>
  <id_info>
    <org_study_id>3475-173</org_study_id>
    <secondary_id>2015-002405-11</secondary_id>
    <nct_id>NCT02622074</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173)</brief_title>
  <official_title>A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) - (KEYNOTE 173)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and clinical activity of
      pembrolizumab (MK-3475) in combination with six chemotherapy regimens as neoadjuvant
      treatment for participants with triple negative breast cancer (TNBC).

      The primary objectives of this study are: 1) to determine the safety and tolerability and 2)
      to establish a recommended Phase 2 dose for the six combination regimens as a neoadjuvant
      treatments for participants with TNBC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Pathological Complete Response (pCR)</measure>
    <time_frame>Up to 27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 27 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Triple Negative Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cohort A: KNp / KAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab (K) PLUS nab-paclitaxel (KNp) followed by pembrolizumab (K) PLUS doxorubicin (A) PLUS cyclophosphamide (C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: KNpCb / KAC Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Regimen 1 of pembrolizumab (K) PLUS nab-paclitaxel (KNp) PLUS carboplatin (Cb) followed by pembrolizumab (K) PLUS doxorubicin (A) PLUS cyclophosphamide (C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: KNpCb / KAC Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Regimen 2 of pembrolizumab (K) PLUS nab-paclitaxel (KNp) PLUS carboplatin (Cb) followed by pembrolizumab (K) PLUS doxorubicin (A) PLUS cyclophosphamide (C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: KNpCb / KAC Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Regimen 3 of pembrolizumab (K) PLUS nab-paclitaxel (KNp) PLUS carboplatin (Cb) followed by pembrolizumab (K) PLUS doxorubicin (A) PLUS cyclophosphamide (C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E: KTCb / KAC Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Regimen 1 of pembrolizumab (K) PLUS paclitaxel (T) PLUS carboplatin (Cb), followed by pembrolizumab (K) PLUS doxorubicin (A) PLUS cyclophosphamide (C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F: KTCb / KAC Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Regimen 2 of pembrolizumab (K) PLUS paclitaxel (T) PLUS carboplatin (Cb) followed by pembrolizumab (K) + doxorubicin (A) PLUS cyclophosphamide (C).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Cohort A: KNp / KAC</arm_group_label>
    <arm_group_label>Cohort B: KNpCb / KAC Regimen 1</arm_group_label>
    <arm_group_label>Cohort C: KNpCb / KAC Regimen 2</arm_group_label>
    <arm_group_label>Cohort D: KNpCb / KAC Regimen 3</arm_group_label>
    <arm_group_label>Cohort E: KTCb / KAC Regimen 1</arm_group_label>
    <arm_group_label>Cohort F: KTCb / KAC Regimen 2</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDAÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Cohort A: KNp / KAC</arm_group_label>
    <arm_group_label>Cohort B: KNpCb / KAC Regimen 1</arm_group_label>
    <arm_group_label>Cohort C: KNpCb / KAC Regimen 2</arm_group_label>
    <arm_group_label>Cohort D: KNpCb / KAC Regimen 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anthracycline (doxorubicin)</intervention_name>
    <description>IV injection</description>
    <arm_group_label>Cohort A: KNp / KAC</arm_group_label>
    <arm_group_label>Cohort B: KNpCb / KAC Regimen 1</arm_group_label>
    <arm_group_label>Cohort C: KNpCb / KAC Regimen 2</arm_group_label>
    <arm_group_label>Cohort D: KNpCb / KAC Regimen 3</arm_group_label>
    <arm_group_label>Cohort E: KTCb / KAC Regimen 1</arm_group_label>
    <arm_group_label>Cohort F: KTCb / KAC Regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Cohort A: KNp / KAC</arm_group_label>
    <arm_group_label>Cohort B: KNpCb / KAC Regimen 1</arm_group_label>
    <arm_group_label>Cohort C: KNpCb / KAC Regimen 2</arm_group_label>
    <arm_group_label>Cohort D: KNpCb / KAC Regimen 3</arm_group_label>
    <arm_group_label>Cohort E: KTCb / KAC Regimen 1</arm_group_label>
    <arm_group_label>Cohort F: KTCb / KAC Regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Cohort B: KNpCb / KAC Regimen 1</arm_group_label>
    <arm_group_label>Cohort C: KNpCb / KAC Regimen 2</arm_group_label>
    <arm_group_label>Cohort D: KNpCb / KAC Regimen 3</arm_group_label>
    <arm_group_label>Cohort E: KTCb / KAC Regimen 1</arm_group_label>
    <arm_group_label>Cohort F: KTCb / KAC Regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Cohort E: KTCb / KAC Regimen 1</arm_group_label>
    <arm_group_label>Cohort F: KTCb / KAC Regimen 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has previously untreated, locally advanced TNBC.

          -  Is able to provide 2 core needle biopsies from the primary tumor at screening to the
             central laboratory and agrees to have a core needle biopsy after single dose
             pembrolizumab treatment if tumor biopsy is feasible as judged by the investigator.

          -  Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Has adequate organ function.

          -  Females of childbearing potential must be willing to use adequate contraception for
             the course of the study through 12 months after the last dose of study drug for
             participants receiving cyclophosphamide and through 6 months after the last dose of
             study drug for participants who do not receive cyclophosphamide.

        Exclusion Criteria:

          -  Has evidence of metastatic breast cancer, concurrent bilateral invasive breast
             cancer, or inflammatory breast cancer.

          -  Has another malignancy within the last 5 years. Exceptions include basal cell
             carcinoma of the skin, squamous cell carcinoma of the skin that has undergone
             potentially curative surgery, or in situ cervical cancer.

          -  Has received prior chemotherapy, targeted therapy, radiation therapy, immunotherapy
             that targets immune checkpoints, co-stimulatory or co-inhibitory pathways for T cell
             receptors within the past 12 months.

          -  Is currently participating and receiving study therapy, or has participated in a
             study of an investigational agent and received study therapy or used an
             investigational device within 4 weeks of the first dose of study drug.

          -  Has received a live vaccine within 30 days of the first dose of study drug.

          -  Has an active autoimmune disease that has required systemic treatment in past 2
             years.

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of
             study drug.

          -  Has a known history of Human Immunodeficiency Virus (HIV).

          -  Has known active Hepatitis B or Hepatitis C.

          -  Has evidence of current pneumonitis.

          -  Has a history of non-infectious pneumonitis requiring treatment with steroids or a
             history of interstitial lung disease.

          -  Has an active infection requiring systemic therapy.

          -  Has significant cardiovascular disease, such as: History of myocardial infarction,
             acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the
             last 6 months; Congestive heart failure (CHF) New York Heart Association (NYHA) Class
             II-IV or history of CHF NYHA class III or IV

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the study.

          -  Is pregnant or breastfeeding, or expecting to conceive children within the projected
             duration of the study, starting with the screening visit through 120 days after the
             last dose of study drug.

          -  Has a known hypersensitivity to the components of the study drug or its analogs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Lassota</last_name>
      <phone>45 44824475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Finland Oy</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pasternack</last_name>
      <phone>358 20 7570300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Sharp &amp; Dohme GmbH</name>
      <address>
        <city>Haar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Medical Information Center</last_name>
      <phone>49 800 673 673 673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Korea LTD</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jongho Ahn</last_name>
      <phone>82-2-331-2000 2015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (I.A.) Corp</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar Recto</last_name>
      <phone>632 784 9500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Mateos Chacon</last_name>
      <phone>(0034) 913210600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Sweden</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tryggve Ljung</last_name>
      <phone>46 (0)70 545 28 66</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ltd.</name>
      <address>
        <city>Hoddesdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Toms</last_name>
      <phone>+44 (0) 1992 452475</phone>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://keynoteclinicaltrials.com</url>
    <description>Merck Oncology Clinical Trial Information</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>December 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Triple Negative Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
